Kiadis Pharma

    OverviewSuggest Edit

    Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands.
    TypePublic
    Founded1997
    HQAmsterdam, NL
    Websitekiadis.com

    Latest Updates

    Employees (est.) (Jan 2017)27
    Job Openings16

    Key People/Management at Kiadis Pharma

    Robert James

    Robert James

    Director

    Kiadis Pharma Office Locations

    Kiadis Pharma has an office in Amsterdam
    Amsterdam, NL (HQ)
    Entrada 231-234
    Show all (1)

    Kiadis Pharma Online and Social Media Presence

    Embed Graph

    Kiadis Pharma News and Updates

    Kiadis Pharma announces results for the six months ended June 30, 2019

    Kiadis to hold conference call with investors today at 15:00 CEST

    Kiadis Pharma Blogs

    Kiadis Pharma launches a private placement of new shares to raise approximately €25 million

    The post Kiadis Pharma launches a private placement of new shares to raise approximately €25 million appeared first on Kiadis Pharma.

    Kiadis Pharma raises €31.2 million in a private placement of 3.9 million new shares

    The post Kiadis Pharma raises €31.2 million in a private placement of 3.9 million new shares appeared first on Kiadis Pharma.

    Kiadis Pharma announces two senior management appointments

    Strengthens Senior Management Team with Chief Human Resources Officer and General Counsel and Company Secretary  Amsterdam, The Netherlands, September 6, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, t…

    Kiadis Pharma announces Financial Results for the six months ended June 30, 2018 and Company update

    Amsterdam, The Netherlands, August 31, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces its unaudited interim Financial Results for the six months ended June 30, 2018, which have been prep…

    Kiadis Pharma announces resignation of Robbert van Heekeren and appoints Scott A. Holmes as new Chief Financial Officer

    Amsterdam, The Netherlands, August 30, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that Robbert van Heekeren is stepping down as Chief Financial Officer, or CFO, and as member of the …

    Kiadis Pharma to attend upcoming investor conferences in September 2018

    Amsterdam, The Netherlands, August 28, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing a patient-specific T-cell product designed to be delivered following a haploidentical hematopoietic stem c…
    Show more

    Kiadis Pharma Frequently Asked Questions

    • When was Kiadis Pharma founded?

      Kiadis Pharma was founded in 1997.

    • Who are Kiadis Pharma key executives?

      Kiadis Pharma's key executives are Robert James.

    • How many employees does Kiadis Pharma have?

      Kiadis Pharma has 27 employees.

    • Who are Kiadis Pharma competitors?

      Competitors of Kiadis Pharma include Loxo Oncology, Keryx Biopharmaceuticals and Parexel International.

    • Where is Kiadis Pharma headquarters?

      Kiadis Pharma headquarters is located at Entrada 231-234, Amsterdam.

    • Where are Kiadis Pharma offices?

      Kiadis Pharma has an office in Amsterdam.

    • How many offices does Kiadis Pharma have?

      Kiadis Pharma has 1 office.